Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
68.45
+0.73 (1.08%)
At close: Nov 20, 2026, 4:00 PM EST
67.65
-0.80 (-1.17%)
After-hours: Nov 20, 2026, 7:48 PM EST
Royalty Pharma Revenue
Royalty Pharma had revenue of $690.10M in the quarter ending September 30, 2026, with 13.26% growth. This brings the company's total for the last twelve months to $2.62B, up 11.36% year-over-year. In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth. That makes Royalty Pharma the 4,191st largest company in the world by revenue and 1,145th in the United States.
Revenue (ttm)
$2.62B
Revenue Growth
+11.36%
P/S Ratio
15.00
Revenue / Employee
$26,168,100
Employees
100
Market Cap
39.26B
Revenue by Segment
- Cystic Fibrosis Franchise 828.18M 34.8%
- Other Products 647.67M 27.2%
- Evrysdi 206.97M 8.7%
- Voranigo 154.42M 6.5%
- Trelegy 154.10M 6.5%
- Tremfya 152.94M 6.4%
- Other Royalty Income and 117.04M 4.9%
- Tysabri 116.88M 4.9%
Fiscal year ended Dec 31, 2025 See the full Royalty Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.38B | 114.62M | 5.06% |
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | 196.96M | 12.33% |
| Dec 31, 2017 | 1.60B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.45B |
| Incyte | 6.01B |
| argenx SE | 5.92B |
| Alnylam Pharmaceuticals | 5.01B |
| Genmab | 4.30B |
| BioNTech SE | 2.75B |
| Moderna | 2.53B |
| Insmed | 1.52B |
RPRX News
- 3 days ago - Royalty Pharma price target raised to $80 from $68 at TD Cowen - TheFly
- 4 days ago - Royalty Pharma Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 8 days ago - Royalty Pharma to present at the UBS Global Biopharma Conference - GlobeNewsWire
- 16 days ago - Royalty Pharma price target raised to $75 from $67 at Morgan Stanley - TheFly
- 16 days ago - Royalty Pharma Slides: Corporate presentation - Filings
- 16 days ago - Royalty Pharma price target raised to $78 from $70 at Citi - TheFly
- 17 days ago - Royalty Pharma price target raised to $74 from $62 at JPMorgan - TheFly
- 17 days ago - Royalty Pharma Earnings Call Transcript: Q3 2026 - Transcripts